Bone-on-a-Chip Systems for Hematological Cancers
Hematological malignancies originating from blood, bone marrow, and lymph nodes include leukemia, lymphoma, and myeloma, which necessitate the use of a distinct chemotherapeutic approach. Drug resistance frequently complicates their treatment, highlighting the need for predictive tools to guide ther...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-03-01
|
| Series: | Biosensors |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2079-6374/15/3/176 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849341477299159040 |
|---|---|
| author | Gül Kozalak Ali Koşar |
| author_facet | Gül Kozalak Ali Koşar |
| author_sort | Gül Kozalak |
| collection | DOAJ |
| description | Hematological malignancies originating from blood, bone marrow, and lymph nodes include leukemia, lymphoma, and myeloma, which necessitate the use of a distinct chemotherapeutic approach. Drug resistance frequently complicates their treatment, highlighting the need for predictive tools to guide therapeutic decisions. Conventional 2D/3D cell cultures do not fully encompass in vivo criteria, and translating disease models from mice to humans proves challenging. Organ-on-a-chip technology presents an avenue to surmount genetic disparities between species, offering precise design, concurrent manipulation of various cell types, and extrapolation of data to human physiology. The development of bone-on-a-chip (BoC) systems is crucial for accurately representing the in vivo bone microenvironment, predicting drug responses for hematological cancers, mitigating drug resistance, and facilitating personalized therapeutic interventions. BoC systems for modeling hematological cancers and drug research can encompass intricate designs and integrated platforms for analyzing drug response data to simulate disease scenarios. This review provides a comprehensive examination of BoC systems applicable to modeling hematological cancers and visualizing drug responses within the intricate context of bone. It thoroughly discusses the materials pertinent to BoC systems, suitable in vitro techniques, the predictive capabilities of BoC systems in clinical settings, and their potential for commercialization. |
| format | Article |
| id | doaj-art-bc6f22e8455b43e4b9b2229ef91f46ac |
| institution | Kabale University |
| issn | 2079-6374 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biosensors |
| spelling | doaj-art-bc6f22e8455b43e4b9b2229ef91f46ac2025-08-20T03:43:37ZengMDPI AGBiosensors2079-63742025-03-0115317610.3390/bios15030176Bone-on-a-Chip Systems for Hematological CancersGül Kozalak0Ali Koşar1Faculty of Engineering and Natural Sciences, Sabancı University, Istanbul 34956, TurkeyFaculty of Engineering and Natural Sciences, Sabancı University, Istanbul 34956, TurkeyHematological malignancies originating from blood, bone marrow, and lymph nodes include leukemia, lymphoma, and myeloma, which necessitate the use of a distinct chemotherapeutic approach. Drug resistance frequently complicates their treatment, highlighting the need for predictive tools to guide therapeutic decisions. Conventional 2D/3D cell cultures do not fully encompass in vivo criteria, and translating disease models from mice to humans proves challenging. Organ-on-a-chip technology presents an avenue to surmount genetic disparities between species, offering precise design, concurrent manipulation of various cell types, and extrapolation of data to human physiology. The development of bone-on-a-chip (BoC) systems is crucial for accurately representing the in vivo bone microenvironment, predicting drug responses for hematological cancers, mitigating drug resistance, and facilitating personalized therapeutic interventions. BoC systems for modeling hematological cancers and drug research can encompass intricate designs and integrated platforms for analyzing drug response data to simulate disease scenarios. This review provides a comprehensive examination of BoC systems applicable to modeling hematological cancers and visualizing drug responses within the intricate context of bone. It thoroughly discusses the materials pertinent to BoC systems, suitable in vitro techniques, the predictive capabilities of BoC systems in clinical settings, and their potential for commercialization.https://www.mdpi.com/2079-6374/15/3/176bone-on-a-chiphematological cancersdisease modellingdrug imaging |
| spellingShingle | Gül Kozalak Ali Koşar Bone-on-a-Chip Systems for Hematological Cancers Biosensors bone-on-a-chip hematological cancers disease modelling drug imaging |
| title | Bone-on-a-Chip Systems for Hematological Cancers |
| title_full | Bone-on-a-Chip Systems for Hematological Cancers |
| title_fullStr | Bone-on-a-Chip Systems for Hematological Cancers |
| title_full_unstemmed | Bone-on-a-Chip Systems for Hematological Cancers |
| title_short | Bone-on-a-Chip Systems for Hematological Cancers |
| title_sort | bone on a chip systems for hematological cancers |
| topic | bone-on-a-chip hematological cancers disease modelling drug imaging |
| url | https://www.mdpi.com/2079-6374/15/3/176 |
| work_keys_str_mv | AT gulkozalak boneonachipsystemsforhematologicalcancers AT alikosar boneonachipsystemsforhematologicalcancers |